Feature|Videos|January 2, 2025
Patient Selection and Recruitment for Clinical Trials
Obtaining the right patient population for a CAR T-cell clinical trial is based off several factors from both the patient and the site.
Advertisement
Episodes in this series
Patient selection is a key component to the success of a clinical trial. A CAR T-cell study protocol is critical in outlining the site, the desired patient diagnosis, biomarkers of the tumor, and prior treatments. Building on key components from episode seven of collaboration, the panelists outline how working close with sites allow for stronger patient selection.
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
Your Questions Answered: AI Drug Discovery, Portfolio Simplification, and a 30-Year First
5